Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Receivables - Net (2016 - 2021)

Historic Receivables - Net for Ernexa Therapeutics (ERNA) over the last 12 years, with Q1 2021 value amounting to $24918.0.

  • Ernexa Therapeutics' Receivables - Net fell 9349.4% to $24918.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $24918.0, marking a year-over-year decrease of 9349.4%. This contributed to the annual value of $1.2 million for FY2019, which is 454.94% up from last year.
  • Per Ernexa Therapeutics' latest filing, its Receivables - Net stood at $24918.0 for Q1 2021, which was down 9349.4% from $132000.0 recorded in Q3 2020.
  • In the past 5 years, Ernexa Therapeutics' Receivables - Net registered a high of $1.8 million during Q1 2017, and its lowest value of $24918.0 during Q1 2021.
  • Over the past 5 years, Ernexa Therapeutics' median Receivables - Net value was $746500.0 (recorded in 2017), while the average stood at $731057.4.
  • In the last 5 years, Ernexa Therapeutics' Receivables - Net surged by 14240.51% in 2020 and then plummeted by 9349.4% in 2021.
  • Over the past 5 years, Ernexa Therapeutics' Receivables - Net (Quarter) stood at $714000.0 in 2017, then soared by 60.08% to $1.1 million in 2018, then rose by 4.55% to $1.2 million in 2019, then tumbled by 88.95% to $132000.0 in 2020, then plummeted by 81.12% to $24918.0 in 2021.
  • Its Receivables - Net was $24918.0 in Q1 2021, compared to $132000.0 in Q3 2020 and $186000.0 in Q2 2020.